Epidemic keratoconjunctivitis (EKC) is an eye infection caused by adenovirus – a worldwide health problem which today lacks efficient treatment. Typical symptoms are acute onset of severe pain, feeling or sensation that a foreign body is present in the eye, watering redness in the conjunctiva, edema and diminishing eyesight. Symptoms include inflammation in the conjunctiva (conjunctivitis) and in the cornea (keratitis). Adenovir Pharma is developing a topical anti-viral pharmaceutical product for treatment of EKC, by preventing adenoviruses from binding to the receptors in the human eye or infecting the corneal cells.

Innovative solution for treatment of viral eye infection

Epidemic keratoconjunctivitis (EKC) is a serious disease and can cause deteriorating vision for the patient. The eye infection also has a vast health economic impact on the society. It is a highly contagious infectious disease which occurs worldwide sporadically and epidemically; thus, it is considered a major health problem in many countries. Today there is no specific anti-viral treatment available to shorten the course of infection, to improve the clinical symptoms, or to prevent the disease.

Adenovir Pharma is developing a topical anti-viral pharmaceutical product for treatment of EKC, by preventing adenoviruses from binding to the receptors in the human eye or infecting the corneal cells. The product – eye drops – acts outside the human cells which should reduce the risk of developing viral resistance. This concept is an effective invention that may also reduce the use of often unnecessarily prescribed antibiotics; thus, it may contribute to the prevention of antibiotic resistance as well.

Innovative treatment solution
One candidate drug  has been chosen for further development – APD-209. The product is topical pharmaceutical product preventing EKC-causing adenoviruses from binding to the receptors in the human eye. The adenoviruses are aggregated and inhibited from binding to and infecting human corneal cells. A second group of novel adenovirus binding molecules has been developed as a second-generation program. APD-514 is the lead candidate developed out of this program and it inhibits adenoviral infection. Learn more about the project.

Our objective
The goal is to develop a topical anti-viral pharmaceutical product for treatment and potential use for prevention of adenoviral conjunctivitis, epidemic keratoconjunctivitis (EKC). It is also important that the final product should be convenient for the patient and reduce the symptoms.